Picture of Fulgent Genetics logo

FLGT — Fulgent Genetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Fulgent Genetics Q3 revenue rises 8% on improved collection rates

Fulgent Genetics Q3 revenue rises 8% on improved collection rates


Overview

  • Genetic testing firm's Q3 revenue rose 8% yr/yr

  • Company posted Q3 non-GAAP net loss of $2.4 mln

  • Company maintained annual revenue guidance and improved non-GAAP loss outlook


Outlook

  • Fulgent maintains 2026 revenue guidance of $330 mln to $340 mln

  • Company now expects 2026 non-GAAP loss of $46 mln to $50 mln

  • Fulgent expects 2026 non-GAAP loss per share of $1.65 to $1.75


Result Drivers

  • COLLECTION RATES - Co said improved collection rates and progress in addressing billing system issues supported Q3 results, per CFO Paul Kim

  • AI INTEGRATION - Co said ongoing integration of AI in laboratory services is improving efficiency and reliability, per CEO Ming Hsieh

  • THERAPEUTICS PIPELINE - Co cited momentum in therapeutics pipeline, including FID-007 and FID-022, as a positive factor, per CEO Ming Hsieh


Company press release: ID:nBwyVgtba


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$90.41 mln

$86.30 mln (1 Analyst)

Q3 Adjusted EBITDA

-$7.5 mln

-$20 mln (1 Analyst)

Q3 Gross Profit

$31.95 mln

Q3 Operating Expenses

$54.49 mln

Q3 Operating Income

-$22.55 mln

Q3 Pretax Loss

$14.04 mln


Analyst Coverage

  • The one available analyst rating on the shares is "hold"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for Fulgent Genetics, Inc. is $19.00, about 3.5% below its November 4 closing price of $19.68


Reuters Recommended Reads

  • Nov 4 - Myriad Genetics Q3 revenue beats analyst estimates, raises FY guidance

  • Nov 4 - Caris Life Sciences' Q3 revenue rises on molecular profiling strength

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Fulgent Genetics

See all news